Dosing & Uses
Dosage Forms & Strengths
powder for inhalation
- 62.5mcg/actuation
Chronic Obstructive Pulmonary Disease
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
62.5 mcg (1 actuation) inhaled PO qDay
Dosage Modifications
Renal impairment (including severe [CrCl <30 mL/min]): No dosage adjustment required
Moderate hepatic impairment (Child-Pugh 7-9): No dosage adjustment required
Severe hepatic impairment: Unknown, not evaluated
Geriatric patients: No dosage adjustment required
Administration
Inhaler is not reusable
Store at room temperature between 68-77°F (20-25°C); excursions permitted from 59-86°F (15-30°C)
Store in a dry place away from direct heat or sunlight
Before the inhaler is used for the first time, the counter should show the number 30 (7 if a sample or institutional pack); this is the number of doses in the inhaler
See prescribing information for detailed description regarding how to administer
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
1-10%
Nasopharyngitis (8%)
Upper respiratory tract infection (5%)
Cough (3%)
Arthralgia (2%
Toothache (1%)
Pharyngitis (1%)
Viral upper respiratory tract infection (1%)
Tachycardia (1%)
<1%
Atrial fibrillation
Postmarketing Reports
Hypersensitivity reactions, including anaphylaxis, angioedema, pruritus, rash, and urticaria
Eye disorders: Eye pain, glaucoma, vision blurred
Renal and urinary disorders: Dysuria, urinary retention
Warnings
Contraindications
Severe hypersensitivity to milk proteins
Demonstrated hypersensitivity to umeclidinium or any of the excipients
Cautions
Anaphylactic reactions reported in patients with severe milk protein allergy after inhalation of other powder products containing lactose (see Contraindications)
Hypersensitivity reactions such as anaphylaxis, angioedema, pruritus, rash, and urticaria may occur; discontinue if reactions occur
Do not initiate in patients during rapidly deteriorating or potentially life-threatening episodes of COPD; not be used for the relief of acute symptoms (ie, as rescue inhaler) from acute episodes of bronchospasm
Paradoxical bronchospasm reported; discontinue and treat immediately with an inhaled, prompt-acting bronchodilator (eg, albuterol)
Worsening of narrow-angle glaucoma may occur
Worsening of urinary retention may occur; caution in patients with prostatic hyperplasia or bladder-neck obstruction
Pregnancy & Lactation
Pregnancy
There are insufficient data on use in pregnant women to inform a drug-associated risk
Animal data
- Administered via inhalation or subcutaneously to pregnant rats and rabbits was not associated with adverse effect on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at maximum recommended human daily inhaled dose (MRHDID)
Lactation
There is no information available on presence of drug in human milk, effects on breastfed child, or on milk production; the drug was detected in plasma of offspring of lactating rats treated with umeclidinium suggesting its presence in maternal milk; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from umeclidinium or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Long-acting muscarinic antagonist (LAMA) often referred to as an anticholinergic; blocks action of acetylcholine at muscarinic receptors (M1 to M5) in the bronchial airways (M3) by preventing increase in intracellular calcium concentration, leading to relaxation of airway smooth muscle, improved lung function, and decreased mucus secretion; dissociates slowly from M3 muscarinic receptors extending its duration of action
Absorption
Plasma levels not predictive of therapeutic effect
Peak plasma time: 5-15 minutes
Distribution
Following IV administration
Protein bound: 89% (umeclidinium)
Vd: 86 L (umeclidinium)
Metabolism
Primarily metabolized by CYP2D6 and is a substrate for the P-gp transporter
Primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (eg, glucuronidation), resulting in a range of metabolites with either reduced pharmacological activity or for which the pharmacological activity has not been established
Systemic exposure to the metabolites is low
Elimination
Half-life: 11 hr
Umeclidinium (IV): 58% feces; 22% urine
Umeclidinium (PO): 92% feces; <1% urine
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.